GlycoMimetics Inc (GLYC)
0.2837
+0.02
(+7.14%)
USD |
NASDAQ |
Jun 26, 09:36
GlycoMimetics Revenue (Annual): 0.01M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.01M |
| December 31, 2022 | 0.075M |
| December 31, 2021 | 1.160M |
| December 31, 2020 | 10.16M |
| December 31, 2019 | |
| December 31, 2018 | |
| December 31, 2017 |
| Date | Value |
|---|---|
| December 31, 2016 | 0.0185M |
| December 31, 2015 | 20.07M |
| December 31, 2014 | 15.03M |
| December 31, 2013 | 3.993M |
| December 31, 2012 | 15.26M |
| December 31, 2011 | 3.814M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
0.01M
Minimum
2023
10.16M
Maximum
2020
2.852M
Average
0.6174M
Median
Revenue (Annual) Benchmarks
| Altimmune Inc | 0.426M |
| Lyell Immunopharma Inc | 0.13M |
| Amicus Therapeutics Inc | 399.36M |
| InfuSystems Holdings Inc | 125.78M |
| Nanoviricides Inc | -- |